The US Food and Drug Administration (FDA) has approved bepirovirsen, sold as Hibsago, the first antisense oligonucleotide treatment for chronic hepatitis B and the first approved therapy designed to help some people achieve a ‘functional cure’.
Developed by GSK and approved on 20 October 2026, bepirovirsen is given as injections under the skin for up to 24 weeks alongside standard antiviral tablets. In the B-Well 1 and 2 trials, 19% of people who received it achieved a functional cure, meaning the virus and its surface protein became undetectable for at least 24 weeks after stopping all treatment, compared with 0% on placebo. Among people with lower starting levels of the virus’s surface protein, 26% achieved this. Chronic hepatitis B affects an estimated 1.7 million people in the US and hundreds of millions worldwide.

Imagine a 45-year-old taxi driver who found out he had hepatitis B when he donated blood twenty years ago. Since then, he has taken an antiviral tablet every day, attended liver scans and worried about passing the virus to his family. His liver is healthy, and the virus is suppressed, but the tablets have become part of his identity. At his clinic, his liver nurse explains that a new injection treatment, added to his tablets for a few months, has helped some people clear the virus’s markers so completely that they can stop all medicines. It won’t work for everyone, and it needs careful monitoring, but for the first time, he imagines a future without daily pills.
What happened
The FDA approved bepirovirsen (Hibsago) on 20 October 2026. It is indicated for adults with chronic hepatitis B without cirrhosis who have taken a nucleos(t)ide analogue antiviral for at least six months, have suppressed hepatitis B DNA, and have a hepatitis B surface antigen (HBsAg) level of 3,000 IU/mL or lower.
Bepirovirsen is given by injection under the skin for up to 24 weeks, alongside existing antiviral therapy. Patients continue their antiviral for at least 24 weeks after the last injection. After the first dose, people may be able to self-inject.
The FDA also authorised the Roche Elecsys HBsAg II quant II RxDx test to help select suitable patients and monitor treatment.
10 key facts
- The FDA approved bepirovirsen (Hibsago) on 20 October 2026.
- It is the first antisense medicine for chronic hepatitis B.
- It is given alongside standard antiviral tablets for up to 24 weeks.
- 19% of people achieved functional cure in the B-Well trials, vs 0% on placebo.
- 26% achieved it if their HBsAg level was 1,000 IU/mL or lower.
- 24% met criteria to stop their antiviral tablets.
- It is for adults without cirrhosis with suppressed virus.
- A boxed warning covers liver flares and low platelets.
- Regular blood tests are needed during treatment.
- Hepatitis B affects about 1.7 million people in the US.
The numbers at a glance
- Approved: 20 October 2026
- Functional cure: 19% (233 of 1,220) vs 0% (0 of 614)
- With HBsAg ≤1,000 IU/mL: 26% (200 of 768) vs 0%
- 24% met criteria to stop antivirals
- Treatment duration: up to 24 weeks
- Antivirals continued for at least 24 weeks after last injection
- Eligible: HBsAg ≤3,000 IU/mL, no cirrhosis
- About 1.7 million people in the US with chronic hepatitis B
What is functional cure?
Hepatitis B is a virus that infects the liver. In chronic hepatitis B, the infection lasts more than six months and can lead to liver scarring (cirrhosis), liver failure and liver cancer.
Current antiviral tablets, such as tenofovir and entecavir, suppress the virus very effectively but rarely clear it. Most people need to take them for life, because the virus’s genetic material remains in liver cells and can reactivate.
A functional cure means that hepatitis B DNA and the surface antigen (HBsAg) are undetectable in the blood for a sustained period after stopping all treatment. The virus is not completely eradicated from the body, but it is controlled by the immune system, similar to people who naturally recover from hepatitis B.
Why this matters
For decades, hepatitis B treatment has meant lifelong tablets. Bepirovirsen is the first approved treatment designed to achieve functional cure in a meaningful proportion of people, potentially allowing them to stop all medication.
Clearing HBsAg is associated with a lower risk of liver cancer and liver disease progression, although long-term data for bepirovirsen are still being collected.
The approval may also open the door to combination treatments aimed at higher cure rates in future.
What officials and experts said
Dr Wendy Carter, acting director of the FDA’s Office of Infectious Diseases, said: ‘For many people living with chronic hepatitis B, treatment can mean taking antiviral medication for years.’
Professor Norah Terrault of USC Keck Medical Center said: ‘This is the start of a new era in treating people living with CHB.’
What this means for you
- If you have chronic hepatitis B, keep taking your antiviral tablets unless advised otherwise.
- Ask your liver team whether bepirovirsen might be suitable and available where you live.
- Know your HBsAg level and liver health status.
- Regular blood tests are needed during treatment to check the liver and platelets.
- Report bruising, bleeding, yellowing of skin or eyes, or dark urine promptly.
- Make sure household contacts and partners are vaccinated against hepatitis B.
What this means for nurses and health workers
Hepatology and viral hepatitis nurses will play a key role in selecting, starting and monitoring patients on bepirovirsen.
- Check eligibility criteria and HBsAg levels.
- Teach safe self-injection.
- Arrange weekly platelet checks and regular liver tests.
- Recognise signs of liver flares.
- Support adherence to antivirals during and after treatment.
- Promote hepatitis B vaccination and testing in families.
The global picture
Hepatitis B is a major global health problem. WHO estimates hundreds of millions of people live with chronic hepatitis B, most in Africa and the Western Pacific, and many don’t know they are infected. Vaccination at birth and testing remain the foundations of prevention. Nigeria is among the countries with a high burden.
Safety and monitoring
Bepirovirsen carries a boxed warning for liver flares during treatment and for low platelet counts (thrombocytopenia). In trials, some people had very high liver enzyme levels, sometimes with raised bilirubin, mostly within the first 12 weeks. It must not be used if platelets are below a certain level, and treatment must stop permanently if platelets fall too low. Liver tests, bilirubin and platelets are monitored, with weekly platelet checks during treatment. Other warnings include worsening kidney function and serious inflammatory reactions. Common side effects include injection site reactions, fever, tiredness and headache.
How antisense medicines work
Antisense oligonucleotides are short strands of genetic material designed to bind to specific RNA messages and stop them being used. Bepirovirsen targets hepatitis B RNA, reducing viral proteins and helping the immune system regain control.
Who is not eligible
People with cirrhosis, high HBsAg levels or uncontrolled virus are not currently eligible. Your liver team will check.
Hepatitis B in Africa
Africa has a high burden of hepatitis B, often acquired at birth or in early childhood. Birth-dose vaccination and testing in pregnancy are vital.
Prevention
The hepatitis B vaccine is safe and highly effective. Babies should receive the first dose within 24 hours of birth.
Living with hepatitis B
With treatment and monitoring, most people with hepatitis B live long, healthy lives. Avoiding alcohol and maintaining a healthy weight protects the liver.
Testing: the first step
Many people with hepatitis B don’t know they have it, because chronic infection often causes no symptoms for years. A simple blood test can diagnose it. Testing is recommended for people born in regions where hepatitis B is common, pregnant women, people living with HIV, household contacts and sexual partners of people with hepatitis B, people who inject drugs, and anyone with abnormal liver tests. If the test is negative, vaccination protects for life. If positive, regular monitoring and treatment when needed greatly reduce the risk of liver damage and cancer. New treatments like bepirovirsen only help people who know their status.
Myths and facts
Myth: Hepatitis B can’t be treated.
Fact: Antivirals control it, and some people may now achieve functional cure.
Myth: Functional cure means the virus is completely gone.
Fact: The virus is controlled but may remain in liver cells.
Myth: Everyone with hepatitis B can use bepirovirsen.
Fact: Specific criteria apply.
Myth: Hepatitis B spreads through sharing food.
Fact: It spreads through blood, sex and from mother to baby.
Questions and answers
What is bepirovirsen?
An antisense medicine for chronic hepatitis B.
How is it given?
Injections under the skin for up to 24 weeks, with antiviral tablets.
How effective is it?
19% achieved functional cure in trials.
Can I stop my tablets?
Only if your team confirms you meet criteria.
What are the risks?
Liver flares and low platelets, among others.
Is it available outside the US?
That depends on approvals in other countries.
Who is eligible?
Adults without cirrhosis, with suppressed virus and HBsAg ≤3,000 IU/mL.
What happens next
GSK is expected to seek approval in other countries. Long-term follow-up will show how durable functional cure is and whether it reduces liver cancer. Studies of combination treatments are ongoing.
Key takeaways
- The FDA approved bepirovirsen (Hibsago) on 20 October 2026.
- It is given alongside standard antiviral tablets for up to 24 weeks.
- 26% achieved it if their HBsAg level was 1,000 IU/mL or lower.
- It is for adults without cirrhosis with suppressed virus.
- Regular blood tests are needed during treatment.
- Hepatitis B affects about 1.7 million people in the US.
How we report health news
Nursing Media Network reports health news using official sources such as the World Health Organization, national public health agencies, medicines regulators and peer-reviewed research, which are linked at the end of each story. Figures in fast-moving stories, such as outbreaks, change quickly, so we state the date each number refers to. If you are reading this later, check the latest update from the official source before making decisions.
News reports describe what has happened across a population. They cannot tell you what is right for your own health. If a story raises questions about your treatment, symptoms or risk, speak to your nurse or healthcare provider before making any changes.
Staying informed without feeling overwhelmed
A constant stream of health headlines can leave people anxious or confused. It can help to choose one or two trusted sources and check them at set times, rather than scrolling throughout the day. Focus on what you can control, such as vaccinations, regular check-ups, healthy routines and knowing when to seek care. Talk about worries with family, friends or your nurse rather than keeping them to yourself, and take a break from news if it is affecting your sleep or mood. Being informed is useful; being overwhelmed is not.
Finding reliable health information
Health information online varies widely in quality. Prefer sources such as the World Health Organization, national health ministries, public health agencies, university hospitals and registered professional bodies. Be cautious with social media posts, miracle cures and products sold with promises that sound too good to be true.
If you read something that worries you or contradicts the advice you have been given, write it down and discuss it with your nurse or healthcare provider. They can explain how it applies to your own situation and help you separate evidence from rumour.
Questions to ask your nurse or healthcare provider
- Am I eligible for bepirovirsen?
- What is my HBsAg level?
- How often will I need blood tests?
- What are the risks for my liver?
- Could I stop my antiviral tablets?
- Should my family be tested and vaccinated?
But if my hepatitis B is controlled on tablets, why consider anything else?
Tablets work well, but most people need them for life. Bepirovirsen offers some people the chance to stop treatment altogether.
Your next step: If you live with hepatitis B, ask your liver nurse about your HBsAg level and whether new treatment options could suit you.
Related: Hepatitis B · Liver cancer · Autoimmune hepatitis
Sources: Contagion Live, 21 October 2026; FDA: novel drug approvals 2026; WHO: hepatitis B.



Leave a Reply